Healthcare companies by risk reading
Healthcare companies by risk reading: 1,214 companies ranked by a composite risk reading built from filed statements -- leverage, cash conversion, operating pressure, customer and supplier concentration and competitive position. Recomputed 1 September 2026.
Composite readings for 8,308 companies, recomputed 1 September 2026. A company appears here once at least three weighted categories cleared their inputs; the rest carry per-mechanism readings without a headline.
| Company | Reading | Band | Sector | Country | Coverage | Market cap |
|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals Inc - Class B LGND | 33 | Normal | Healthcare | United States | 4 / 6 | $5.7B |
| MiniMed Group, Inc. MMED | 56 | Elevated | Healthcare | United States | 5 / 6 | $5.7B |
| Amneal Pharmaceuticals Inc - Class A AMRX | 39 | Normal | Healthcare | United States | 5 / 6 | $5.6B |
| CRISPR Therapeutics AG CRSP | 46 | Elevated | Healthcare | Switzerland | 4 / 6 | $5.5B |
| Merit Medical Systems Inc MMSI | 37 | Normal | Healthcare | United States | 5 / 6 | $5.4B |
| Sotera Health Company SHC | 32 | Normal | Healthcare | United States | 5 / 6 | $5.4B |
| Apellis Pharmaceuticals Inc APLS | 23 | Normal | Healthcare | United States | 5 / 6 | $5.3B |
| Galenica Sante AG GALE | 44 | Elevated | Healthcare | Switzerland | 5 / 6 | $5.1B |
| Waystar Holding Corp WAY | 38 | Normal | Healthcare | United States | 4 / 6 | $5.0B |
| Acadia Pharmaceuticals Inc ACAD | 22 | Normal | Healthcare | United States | 5 / 6 | $5.0B |
| Doximity Inc - Class A DOCS | 30 | Normal | Healthcare | United States | 5 / 6 | $4.8B |
| LifeStance Health Group Inc LFST | 32 | Normal | Healthcare | United States | 5 / 6 | $4.7B |
| Haemonetics Corp HAE | 47 | Elevated | Healthcare | United States | 4 / 6 | $4.7B |
| Hikma Pharmaceuticals PLC H5P | 44 | Elevated | Healthcare | United Kingdom | 5 / 6 | $4.6B |
| Amicus Therapeutics Inc FOLD | 36 | Normal | Healthcare | United States | 5 / 6 | $4.5B |
| Ottobock SE & Co. KGaA OBCK | 41 | Elevated | Healthcare | Germany | 5 / 6 | $4.4B |
| LivaNova PLC LIVN | 36 | Normal | Healthcare | United Kingdom | 5 / 6 | $4.4B |
| Envista Holdings Corp NVST | 49 | Elevated | Healthcare | United States | 4 / 6 | $4.4B |
| Heartflow Inc HTFL | 62 | Stretched | Healthcare | United States | 5 / 6 | $4.3B |
| ICU Medical Inc ICUI | 55 | Elevated | Healthcare | United States | 5 / 6 | $4.3B |
| Concentra Group Holdings Parent Inc CON | 43 | Elevated | Healthcare | United States | 5 / 6 | $4.3B |
| Integer Holdings Corp ITGR | 41 | Elevated | Healthcare | United States | 5 / 6 | $4.3B |
| Billiontoone Inc - Class A BLLN | 34 | Normal | Healthcare | United States | 5 / 6 | $4.2B |
| Ansell Ltd ANN | 32 | Normal | Healthcare | Australia | 3 / 6 | $4.1B |
| Indivior Plc INDV | 49 | Elevated | Healthcare | United States | 4 / 6 | $4.1B |
| Siegfried Holding Ltd SFZN | 54 | Elevated | Healthcare | Switzerland | 4 / 6 | $4.1B |
| Relay Therapeutics Inc RLAY | 45 | Elevated | Healthcare | United States | 4 / 6 | $4.0B |
| Adaptive Biotechnologies Corp ADPT | 52 | Elevated | Healthcare | United States | 5 / 6 | $4.0B |
| iRhythm Technologies Inc IRTC | 60 | Stretched | Healthcare | United States | 4 / 6 | $3.9B |
| Aspen Pharmacare Holdings Limited LDZA | 53 | Elevated | Healthcare | South Africa | 5 / 6 | $3.9B |
| Legend Biotech Corp LEGN | 41 | Elevated | Healthcare | United States | 5 / 6 | $3.9B |
| Catalyst Pharmaceuticals Inc CPRX | 17 | Contained | Healthcare | United States | 4 / 6 | $3.9B |
| Telix Pharmaceuticals Ltd TLX | 48 | Elevated | Healthcare | Australia | 4 / 6 | $3.8B |
| Arcus Biosciences Inc RCUS | 72 | Stretched | Healthcare | United States | 5 / 6 | $3.7B |
| Iovance Biotherapeutics Inc IOVA | 43 | Elevated | Healthcare | United States | 5 / 6 | $3.7B |
| Santen Pharmaceutical Co. Ltd SZD | 46 | Elevated | Healthcare | Japan | 3 / 6 | $3.7B |
| Amplifon S.p.A AXNA | 48 | Elevated | Healthcare | Italy | 3 / 6 | $3.7B |
| SIMCERE PHARMAC. GRP LTD S2P | 34 | Normal | Healthcare | China | 5 / 6 | $3.6B |
| MEDIPAL HOLDINGS CORP. 59Z | 57 | Elevated | Healthcare | Japan | 4 / 6 | $3.6B |
| Organon & Company OGN | 53 | Elevated | Healthcare | United States | 5 / 6 | $3.6B |
| Laboratorios Farmaceuticos ROVI ROVI | 33 | Normal | Healthcare | Spain | 4 / 6 | $3.6B |
| Pulse Biosciences Inc PLSE | 65 | Stretched | Healthcare | United States | 4 / 6 | $3.6B |
| China Resources Pharmaceutical Group Limited 640 | 50 | Elevated | Healthcare | Hong Kong | 5 / 6 | $3.6B |
| GRAIL Inc GRAL | 47 | Elevated | Healthcare | United States | 4 / 6 | $3.5B |
| Ideaya Biosciences Inc IDYA | 34 | Normal | Healthcare | United States | 5 / 6 | $3.5B |
| AbCellera Biologics Inc ABCL | 77 | Stretched | Healthcare | Canada | 4 / 6 | $3.5B |
| Option Care Health Inc OPCH | 41 | Elevated | Healthcare | United States | 4 / 6 | $3.5B |
| China Medical System Holdings Limited 2M7C | 52 | Elevated | Healthcare | Hong Kong | 5 / 6 | $3.5B |
| Veracyte Inc VCYT | 23 | Normal | Healthcare | United States | 5 / 6 | $3.5B |
| BIOCYTOGEN PHARMA. H YC1 I54 | 16 | Contained | Healthcare | China | 5 / 6 | $3.4B |
| National Healthcare Corp NHC | 28 | Normal | Healthcare | United States | 5 / 6 | $3.4B |
| uniQure N.V. QURE | 74 | Stretched | Healthcare | Netherlands | 5 / 6 | $3.4B |
| Tango Therapeutics Inc TNGX | 36 | Normal | Healthcare | United States | 5 / 6 | $3.3B |
| ANSELL (UNSP.ADRS)/4 PD1 | 48 | Elevated | Healthcare | Australia | 4 / 6 | $3.2B |
| Tarsus Pharmaceuticals Inc TARS | 42 | Elevated | Healthcare | United States | 5 / 6 | $3.2B |
| Virbac SA VIRP | 38 | Normal | Healthcare | France | 5 / 6 | $3.1B |
| Celldex Therapeutics Inc CLDX | 68 | Stretched | Healthcare | United States | 5 / 6 | $3.1B |
| Immunome Inc IMNM | 59 | Elevated | Healthcare | United States | 4 / 6 | $3.1B |
| MEDACTA GROUP S.A. SF-,10 6MD | 39 | Normal | Healthcare | Switzerland | 5 / 6 | $3.1B |
| Warby Parker Inc - Class A WRBY | 35 | Normal | Healthcare | United States | 5 / 6 | $3.0B |
| Beam Therapeutics Inc BEAM | 36 | Normal | Healthcare | United States | 5 / 6 | $3.0B |
| Arcutis Biotherapeutics Inc ARQT | 43 | Elevated | Healthcare | United States | 5 / 6 | $3.0B |
| BioArctic AB (publ) BIOA-B | 52 | Elevated | Healthcare | Sweden | 3 / 6 | $3.0B |
| NewAmsterdam Pharma Company NV NAMS | 70 | Stretched | Healthcare | Netherlands | 5 / 6 | $3.0B |
| Transmedics Group Inc TMDX | 22 | Normal | Healthcare | United States | 5 / 6 | $2.9B |
| Aveanna Healthcare Holdings Inc AVAH | 48 | Elevated | Healthcare | United States | 3 / 6 | $2.9B |
| Tecan Group AG TECN | 62 | Stretched | Healthcare | Switzerland | 5 / 6 | $2.9B |
| KEYMED BIOSCIENCES -0001 64Z | 47 | Elevated | Healthcare | China | 5 / 6 | $2.9B |
| Zai Lab Ltd ZLAB | 41 | Elevated | Healthcare | China | 5 / 6 | $2.9B |
| Brookdale Senior Living Inc BKD | 66 | Stretched | Healthcare | United States | 4 / 6 | $2.8B |
| Alumis Inc ALMS | 60 | Stretched | Healthcare | United States | 4 / 6 | $2.8B |
| Soleno Therapeutics Inc SLNO | 35 | Normal | Healthcare | United States | 4 / 6 | $2.8B |
| Axogen Inc AXGN | 54 | Elevated | Healthcare | United States | 5 / 6 | $2.7B |
| ATAI Life Sciences N.V. ATAI | 58 | Elevated | Healthcare | United States | 4 / 6 | $2.7B |
| EBOS Group Limited EJG | 54 | Elevated | Healthcare | Australia | 4 / 6 | $2.7B |
| Nurix Therapeutics Inc NRIX | 35 | Normal | Healthcare | United States | 5 / 6 | $2.7B |
| Viridian Therapeutics Inc VRDN | 53 | Elevated | Healthcare | United States | 4 / 6 | $2.6B |
| Almirall S.A E2Z | 50 | Elevated | Healthcare | Spain | 3 / 6 | $2.6B |
| Privia Health Group Inc PRVA | 37 | Normal | Healthcare | United States | 5 / 6 | $2.6B |
| Duality Biotherapeutics, Inc. 4ZB | 44 | Elevated | Healthcare | China | 5 / 6 | $2.6B |
| Caredx Inc CDNA | 40 | Elevated | Healthcare | United States | 5 / 6 | $2.6B |
| Supernus Pharmaceuticals Inc SUPN | 53 | Elevated | Healthcare | United States | 4 / 6 | $2.6B |
| GeneDx Holdings Corp - Class A WGS | 36 | Normal | Healthcare | United States | 5 / 6 | $2.5B |
| Neogen Corp NEOG | 64 | Stretched | Healthcare | United States | 4 / 6 | $2.5B |
| Acadia Healthcare Company Inc ACHC | 63 | Stretched | Healthcare | United States | 4 / 6 | $2.5B |
| Precigen Inc PGEN | 80 | Acute | Healthcare | United States | 4 / 6 | $2.5B |
| Ultragenyx Pharmaceutical Inc RARE | 44 | Elevated | Healthcare | United States | 5 / 6 | $2.5B |
| Biocryst Pharmaceuticals Inc BCRX | 15 | Contained | Healthcare | United States | 5 / 6 | $2.5B |
| Atricure Inc ATRC | 35 | Normal | Healthcare | United States | 5 / 6 | $2.5B |
| Prestige Consumer Healthcare Inc PBH | 33 | Normal | Healthcare | United States | 4 / 6 | $2.5B |
| Bausch Health Companies Inc BHC | 51 | Elevated | Healthcare | Canada | 4 / 6 | $2.4B |
| Oxford Nanopore Technologies Ltd ONT | 62 | Stretched | Healthcare | United Kingdom | 5 / 6 | $2.4B |
| Guardian Pharmacy Services Inc GRDN | 29 | Normal | Healthcare | United States | 5 / 6 | $2.3B |
| SHANGHAI JUNSHI BIO YC1 8SJ | 54 | Elevated | Healthcare | China | 5 / 6 | $2.3B |
| Nuvation Bio Inc - Class A NUVB | 67 | Stretched | Healthcare | United States | 4 / 6 | $2.3B |
| UFP Technologies Inc UFPT | 34 | Normal | Healthcare | United States | 5 / 6 | $2.3B |
| Ocular Therapeutix Inc OCUL | 71 | Stretched | Healthcare | United States | 5 / 6 | $2.3B |
| GRAND PHARM. GRP. HD-01 MX6A | 51 | Elevated | Healthcare | Hong Kong | 5 / 6 | $2.3B |
| Neogenomics Inc NEO | 62 | Stretched | Healthcare | United States | 5 / 6 | $2.3B |
| Harmony Biosciences Holdings Inc HRMY | 24 | Normal | Healthcare | United States | 5 / 6 | $2.3B |
By sector
Industrials 1,536Technology 1,292Healthcare 1,214Consumer Cyclical 1,116Basic Materials 577Communication Services 565Real Estate 552Consumer Defensive 536Energy 356Utilities 232
How the reading is built
Each company is scored on six mechanisms -- market expectation, operating pressure, cash conversion, leverage, concentration and competitive position -- from its own filed statements. A mechanism whose inputs do not clear its coverage floor is left unread rather than scored zero, and a reading built on thin coverage is pulled toward a neutral prior rather than claiming safety from what nobody looked at.
Descriptive, not advisory. These bands describe measured mechanisms; they are not investment advice, not a forecast, and not a statement about whether a share is worth owning.